On December 18, 2025, Yousha Neman-Ebrahim, Chief Clinical Officer, adopted a written plan for the sale of shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 25% of the net shares of common stock issued to Mr. Neman-Ebrahim upon each vesting of shares of restricted stock, with the actual number of shares subject to each sale to be determined at the time of the applicable vesting event. The plan will expire on March 18, 2027, or on any earlier date on which all of the shares authorized for sale have been sold.

On December 18, 2025, Axel Schonthal, Directors, adopted a written plan for the sale of up to 8,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on January 17, 2027, or on any earlier date on which all of the shares have been sold.

On June 16, 2026, Thomas Chen, Founder and Chief Medical Officer, adopted a written plan for the sale of up to 40,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on September 15, 2027, or on any earlier date on which all of the shares have been sold.

On June 16, 2026, Keithly Garnett, Chief Financial Officer, adopted a written plan for the sale of up to 50,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on September 15, 2027, or on any earlier date on which all of the shares have been sold.

On June 16, 2026, David Choi, Chief Accounting Officer, adopted a written plan for the sale of up to 22,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on September 15, 2027, or on any earlier date on which all of the shares have been sold.

On June 17, 2026, Jim Delshad, Directors, adopted a written plan for the sale of up to 15,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on September 16, 2027, or on any earlier date on which all of the shares have been sold.

On June 23, 2026, Ming-Fu Chiang, Directors, adopted a written plan for the sale of up to 55,000 shares of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan will expire on September 26, 2027, or on any earlier date on which all of the shares have been sold.